247 results on '"Welte Tobias"'
Search Results
2. Clinical factors linked to the type of respiratory medication in COPD: Results from COSYCONET
3. The bronchiectasis exacerbation definition in a real-world setting: data from the EMBARC registry
4. The microbiology of bronchiectasis in Europe: Data from the European Bronchiectasis Registry (EMBARC)
5. Proteinase 3 as a marker of clinical severity in bronchiectasis: Data from the EMBARC-BRIDGE study
6. Effects of patient serum containing different profiles and magnitudes of inflammatory markers on human microvascular lung endothelial and bronchial epithelial cells
7. Sputum colour assessment and clinical outcomes in bronchiectasis: data from the EMBARC Registry
8. Pseudomonas aeruginosa eradication in patients with bronchiectasis: data from the EMBARC registry
9. Late Breaking Abstract - Diversity of endothelial cells in restrictive allograft syndrome
10. Increasing CRPM levels following antifibrotic therapy in IPF is associated with adverse outcomes with nintedanib, but not pirfenidone
11. Treatment with low-molecular-weight heparin negatively effects lung cancer patient survival
12. Vilobelimab’s effect on mortality in severe COVID-19 ARDS patients: Phase 3 RCT
13. “Super Survivor” after Lung Transplantation – Protective Role of Macrophages?
14. Morphomolecular analysis of the capillary network in alveolar capillary dysplasia
15. Alpha-1 antitrypsin deficiency genotypes in a large international cohort study of bronchiectasis (EMBARC BRIDGE)
16. Convergent validity of the Bronchiectasis Impact Measure: data from the EMBARC-BRIDGE study
17. Validation of the Rose Criteria for COPD-Bronchiectasis Overlap: Data from the European Bronchiectasis Registry (EMBARC)
18. Neutrophil metabolomics in bronchiectasis: data from the EMBARC BRIDGE study
19. Blood eosinophils, inhaled corticosteroids and exacerbations in bronchiectasis: Data from the EMBARC registry
20. Plasma levels of α1-antitrypsin-derived C-terminal peptides in PiMM and PiZZ COPD patients.
21. Future directions: diagnostic approaches and therapy with AAT
22. The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus.
23. Update June 2022: management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline [editorial]
24. Update March 2022: management of hospitalised adults with coronavirus disease-19 (COVID-19): a European Respiratory Society living guideline [editorial]
25. Inhaled corticosteroids for the treatment of COVID-19.
26. Preface
27. Characteristics and outcomes of adults with primary ciliary dyskinesia (PCD): an EMBARC/BEAT-PCD analysis
28. Clinical decision making is improved by rapid multiplex-PCR in suspected lower respiratory tract infection after lung transplantation in a prospective cohort study
29. Late Breaking Abstract - Role of matrix metalloproteinase-2 and -9 in experimental lung fibrosis in mice
30. The microbiology of stable bronchiectasis: data from the EMBARC bronchiectasis registry
31. Deteriorating heath status in bronchiectasis : longitudinal data from the EMBARC registry
32. The prevalence and impact of autoantibodies among people with bronchiectasis: a data analysis of the EMBARC registry
33. Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR
34. Late Breaking Abstract - B cells are not involved in the regulation of adenoviral TGF-ß1- or bleomycin-induced lung fibrosis in mice
35. COPD maintenance therapy is related to left heart size: Results from the multicenter long-term observation COSYCONET
36. Does acute phase protein alpha1-antitrypsin modulate apoptosis-autophagy crosstalk resulting in resistance of NSCLC cells to cancer drugs?
37. Treatment with inhaled corticosteroids in COPD groups GOLD A and B –relationship to clinical state in the COSYCONET cohort
38. A specific monoclonal antibody targeting C-36 peptide of alpha1-antitrypsin as a tool in respiratory research
39. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
40. The NLRP3-inflammasome-caspase-1 pathway is upregulated in idiopathic pulmonary fibrosis and acute exacerbations and is inducible by apoptotic A549 cells
41. Characterisation of eosinophilic bronchiectasis: A European multicohort study
42. Quality of care in bronchiectasis using the European Respiratory Society Guidelines as a reference standard- data from the EMBARC registry
43. Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells
44. Inhaled corticosteroids use in patients with bronchiectasis: Data from the EMBARC registry
45. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities
46. Late Breaking Abstract - Chronic coronary artery disease and decline of lung function as predictors of mortality and exacerbation risk in stable COPD: Results from COSYCONET
47. Pneumonia and other infectious diseases
48. Epidemiology of CAP in Europe
49. Pneumococcal and influenza vaccination
50. Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards [editorial]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.